Efficacy and safety of envafolimab plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer: A prospective, single-arm, phase II trial. This is an ASCO Meeting ...
We report phase I results for obrixtamig (BI 764532), a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager, in patients with previously treated DLL3-positive small cell lung cancer (SCLC), ...
Octreotide scintigraphy versus DOTATOC PET: Concordance of Krenning scores and implications on PRRT treatment eligibility. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
DUBLIN--(BUSINESS WIRE)--The "DLL3 Targeted Therapies Market, Approved Drugs, Dosage, Pricing & Clinical Trials Insight 2025" report has been added to ResearchAndMarkets.com's offering. Delta-like ...
Neuroendocrine carcinomas (NECs), which include small-cell lung cancer (SCLC), are a highly heterogeneous group of aggressive cancers with poor prognosis, noted Martin Wermke, MD, of TU Dresden ...
Molecular Partners announced positive IND-enabling data for MP0712 and preclinical findings for novel targeted Radio-DARPins at AACR 2025. Molecular Partners AG announced positive IND-enabling data ...
DLL3 expression on circulating tumor cells may predict Imdelltra response in small cell lung cancer patients, aiding personalized treatment decisions. High DLL3 expression correlates with positive ...
Please provide your email address to receive an email when new articles are posted on . MADRID — A novel T-cell engager appeared safe and exhibited efficacy as treatment for neuroendocrine tumors, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results